- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01547260
Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic Cancer (LENAGEM)
Phase I/II Study of Lenalidomide and Gemcitabine as First-line Treatment in Patients With Locally Advanced or Metastatic Pancreatic Cancer
Study Overview
Status
Intervention / Treatment
Detailed Description
Pancreatic cancer is characterised by aggressive growth, treatment resistance and an extremely poor prognosis. In subjects with locally advanced or metastatic disease, the median survival is approximately 6 - 11 months and 2 - 6 months, respectively. The currently accepted treatment for this disease in EU is gemcitabine which supplanted treatment with 5-FU after it was shown that median survival duration was marginally improved (4.41 and 5.65 months respectively, p = 0,022). The reported median survival time for subjects treated with single-agent gemcitabine in randomized phase III studies ranged form 4.9 to 7.2 months. Despite these improvements in the treatment of pancreatic cancer, the prognosis remains very poor. Lenalidomide (Revlimid®) belongs to a proprietary class of compounds called immunomodulatory drugs (IMiDs). IMiDshave both immunomodulatory and anti-angiogenic properties which could confer antitumour and antimetastatic effects. Lenalidomide has been demonstrated to possess anti-angiogenic activity through inhibition of bFGF, VEGF and TNF-alpha induced endothelial cell migration, due at least in part to inhibition of Akt phosphorylation response to bFGF.In addition, lenalidomide has a variety of immunomodulatory effects. Gemcitabine (Gemzar®) is a synthetic pyrimidine nucleoside analogue that is used as standard treatment of advanced pancreatic cancer. Beside the cytotoxic activity of gemcitabine, accumulating evidence has indicated that the product promote specific anticancer immune responses that contribute to the therapeutic effects of conventional therapy.Down-regulation in survival rate of pancreatic cell lines has more recently been observed, when treated with lenalidomide and gemcitabine in sub-optimal concentrations.Those data supports a hypothesis of a potential hyper-additive affect of the treatments given in combination. Therefore lenalidomide and gemcitabine should be of major interest to explore for combination therapy.
This is a phase I/II open-label, multi-center study. It will consist of a phase I dose-finding part and a phase II part during which subjects will be treated at the MTD established during phase I. Lenalidomide will be administered by a stepwise dose-escalation schedule in the phase I part. Thus, the primary endpoint in the phase I part is to determine the MTD and safety of the regimen lenalidomide and gemcitabine as first-line treatment in subjects with advanced pancreatic cancer.In the phase II part, primary endpoint is to evaluate the immunomodulatory effects of lenalidomide in combination with gemcitabine in the same patient population.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Solna
-
Stockholm, Solna, Sweden, 171 76
- Karolinska University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically or cytologically confirmed, unresectable, locally advanced, or metastatic adenocarcinoma of the pancreas.
- ECOG performance status of 0 or 1, see Appendix 1.
- Life expectancy > 12 weeks.
- Must understand and voluntarily sign an informed consent form.
- Age > 18 years at the time of signing informed consent form.
- Must be able to adhere to the study visit schedule and other protocol requirements.
Female subjects of childbearing potential† must:
- Understand that the study medication is expected to have a teratogenic risk
- Agree to use, and be able to comply with, effective contraception without interruption, 4 weeks before starting study drug, throughout study drug therapy (including dose interruptions) and for 4 weeks after the end of study drug therapy, even if she has amenorrhoea
Male subjects must:
- Agree to use condoms throughout study drug therapy, during any dose interruption and for one week after cessation of study therapy if their partner is of childbearing potential and has no contraception.
- Agree not to donate semen during study drug therapy and for one week after end of study drug therapy
Exclusion Criteria:
- Prior use of systemic chemotherapy for the treatment of adenocarcinoma of the pancreas (with the exception of gemcitabine, fluorouracil, or capecitabine in the adjuvant setting).
- Laboratory abnormalities:
- Prior history of malignancy within 5 years (except basal or squamous cell carcinoma or carcinoma in situ of the cervix or breast, localized prostate cancer with PSA < 1,0 mg/dL).
- Subjects with a history of or active DVT or PE that are not therapeutically managed on a stable dose of appropriate anticoagulant.
- Brain metastases (subjects that are asymptomatic and do not require steroid control may be enrolled at the discretion of the investigator).
- Surgery within 28 days prior to cycle 1 Day 1 (minimally invasive procedures for the purpose of diagnosis or staging of the disease are permitted, including stent placement and insertion of central venous access advice).
- Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
- Any serious medical condition or psychiatric illness that places the subject at an unacceptable risk for study participation or would prevent the subject from signing the informed consent form.
- Prior therapy with lenalidomide or thalidomide.
- Use of any other experimental drug or therapy within 28 days prior to Cycle 1 Day 1.
- Pregnant or lactating females.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Lenalidomide
Phase I; Lenalidomide capsules will be taken orally each day on days 1-21 of each 28-day cycle.
3 subjects will be enrolled into each dose cohort for 15, 20 and 25 mg/day.
Gemcitabine, 1000 mg/m2 in 0.9% sodium chloride will be administered iv over 30 minutes, at days 1, 8, 15 of each 28-day cycle.
Phase II: Every other consecutive included subject in phase II part will be treated with either single lenalidomide (days 1-21 of 28) or single gemcitabine (days 1, 8, 15 of 28) during Cycle 1.
The first included patient in phase II part will start with single lenalidomide.
From treatment cycle number 2 and beyond, all subjects in the phase II part of the study will be treated with lenalidomide in combination with gemcitabine.
|
Gemcitabine (Gemzar®), 1000 mg/m2 in 0.9% sodium chloride will be administered as intravenous infusion over 30 minutes, weekly for 3 weeks then rest for 1 week (days 1, 8, 15 of each 28-day cycle).
Other Names:
|
EXPERIMENTAL: gemcitabine
Gemcitabine, 1000 mg/m2 in 0.9% sodium chloride will be administered iv over 30 minutes, at days 1, 8, 15 of each 28-day cycle in both phase I and II.
Phase I:Lenalidomide capsules will be taken orally each day on days 1-21 of each 28-day cycle.
3 subjects will be enrolled into each dose cohort for 15, 20 and 25 mg/day.
Phase II: Every other consecutive included subject in phase II part will be treated with either single lenalidomide (days 1-21 of 28) or single gemcitabine (days 1, 8, 15 of 28) during Cycle 1.
The first included patient in phase II part will start with single lenalidomide.
From treatment cycle number 2 and beyond, all subjects in the phase II part of the study will be treated with lenalidomide in combination with gemcitabine.
|
Lenalidomide capsules will be taken orally in the morning each day on days 1-21 of each 28-day cycle.
Phase I; Three subjects will be enrolled into each dose cohort for 15, 20 and 25 mg/day, respectively.
Phase II; Lenalidomide at dose determined in Phase I, will be administered orally once daily for 21 days followed by 7 days rest.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety (phase I).
Time Frame: Within the first day after start of treatment until 30 days post the last dose of study drug.
|
In the phase I part of the study, the primary outcome is to determine the MTD and safety of the regimen lenalidomide and gemcitabine in combination.
Data from all subjects who receive any study drug will be included in the safety analyses, according to the NCI CTCAE v3.0.
|
Within the first day after start of treatment until 30 days post the last dose of study drug.
|
Immunomodulatory effect (phase II).
Time Frame: Within the first day of treatment until 60 days after start of treatment.
|
In the phase II part, the primary endpoint is to evaluate assessment of immunological reaction.The changes in immune responses at the end of cycle 1 (single lenalidomide or single gemcitabine) and cycle 2 (lenalidomide combined with gemcitabine) will be described in relation to baseline within the individual patient.
|
Within the first day of treatment until 60 days after start of treatment.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical efficacy
Time Frame: Within start of treatment until start of therapy until clinical and/or radiological signs of progression of the disease by treatment group together.
|
Progression-free survival (PFS) will be presented as time from start of therapy until clinical and/or radiological signs of progression of the disease by treatment group together. Survival rate at 12 months will be presented as rate of patients still alive at 12 months after start of therapy by treatment group together. Overall survival (OS) will be presented as time from start of therapy until death by treatment group together. |
Within start of treatment until start of therapy until clinical and/or radiological signs of progression of the disease by treatment group together.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Håkan Mellstedt, Prof., Karolinska University Hospital
Publications and helpful links
General Publications
- Ullenhag GJ, Mozaffari F, Broberg M, Mellstedt H, Liljefors M. Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer. PLoS One. 2017 Jan 18;12(1):e0169736. doi: 10.1371/journal.pone.0169736. eCollection 2017.
- Ullenhag GJ, Rossmann E, Liljefors M. A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer. PLoS One. 2015 Apr 2;10(4):e0121197. doi: 10.1371/journal.pone.0121197. eCollection 2015.
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Pancreatic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Gemcitabine
- Lenalidomide
Other Study ID Numbers
- LENAGEM-PANC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Ductal Adenocarcinoma
-
Roswell Park Cancer InstituteNot yet recruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma and other conditionsUnited States
-
Georgetown UniversityERYtech PharmaActive, not recruitingMetastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
Gilead SciencesTerminatedPreviously Untreated Pancreatic Ductal Adenocarcinoma | Relapsed/Refractory Pancreatic Ductal AdenocarcinomaUnited States
-
SOFIERecruitingFAP | PDAC - Pancreatic Ductal AdenocarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Metastatic Pancreatic Cancer | Metastatic Pancreatic Ductal Adenocarcinoma | Primary Pancreatic Ductal AdenocarcinomaUnited States
-
UMC UtrechtDutch Pancreatic Cancer Group (DPCG)Enrolling by invitationResectable Pancreatic Ductal Adenocarcinoma | Recurrent Pancreatic Ductal AdenocarcinomaNetherlands
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Bristol-Myers SquibbRecruitingPancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)United States
-
OHSU Knight Cancer InstituteGenentech, Inc.; Oregon Health and Science University; American Association for... and other collaboratorsRecruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal AdenocarcinomaUnited States
-
Sohag UniversityCompletedPancreatic Adenocarcinoma
Clinical Trials on Gemzar
-
Patrick Dillon, MDRecruitingBreast Cancer | Breast NeoplasmsUnited States
-
AmgenTerminatedAdenocarcinoma of the Pancreas | Locally Advanced | UnresectableSpain, Belgium, Denmark, Poland, United States, Korea, Republic of, Russian Federation, Austria, Portugal, United Kingdom, Germany, Hungary, Czech Republic
-
National Institute of CancerologíaInstituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran; Instituto...Recruiting
-
AmpliMed CorporationCompletedPancreatic NeoplasmsUnited States
-
Arecor LimitedCompleted
-
University of Colorado, DenverChildren's Hospital ColoradoActive, not recruitingDiffuse Intrinsic Pontine GliomaUnited States
-
University of FloridaCompleted
-
Samuel Lunenfeld Research Institute, Mount Sinai...Completed
-
K-Group, Beta, Inc., a wholly owned subsidiary...Active, not recruitingOsteosarcomaUnited States, France
-
CureLab OncologyActive, not recruitingOvarian Cancer | Platinum-resistant Ovarian CancerBelarus